OncoMatch/Clinical Trials/NCT06855771
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Is NCT06855771 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies BMS-986504 for carcinoma, non-small-cell lung.
Treatment: BMS-986504 — The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MTAP homozygous deletion
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: any prior systemic therapy
progression on prior therapies at the time of enrollment
Cannot have received: PRMT5 inhibitor
Prior treatment with a PRMT5 or MAT2A inhibitor
Cannot have received: MAT2A inhibitor
Prior treatment with a PRMT5 or MAT2A inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alaska Oncology and Hematology · Anchorage, Alaska
- Local Institution - 0099 · Boise, Idaho
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Karmanos Cancer Institute · Detroit, Michigan
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06855771 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PRMT5 inhibitor, MAT2A inhibitor disqualifies patients from enrollment.
Does this trial require MTAP?
Yes, MTAP homozygous deletion is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages